Skip to main content
. 2017 Mar 15;56(6):631–636. doi: 10.2169/internalmedicine.56.7797

Figure 2.

Figure 2.

The changes in bone mineral density (BMD) from baseline to 12 months after denosumab therapy. The BMD data expressed as a percentage of the young adult means (%YAM) were compared between baseline and 12 months after denosumab therapy. (A) A significant gain occurred in BMD at the lumbar spine (LSBMD) (from 91.5 to 95.0 %YAM) (p=0.00064). (B) A significant gain occurred in BMD at the femoral neck (FNBMD) (from 86.4 to 89.4 %YAM) (p=0.0002). Open circles indicate means.